NOTCH1 and acute lymphoblastic leukemia: However, both the substantial toxicity of GSIs on other tissues and the relative ease of T-ALL tumors to mutate and develop resistance have highlighted the need for better therapeutic strategies to mitigate oncogenic NOTCH1 and treat T-ALL10,11.